OraSure Technologies, Inc. (NASDAQ:OSUR) Director John P. Kenny Acquires 47,659 Shares

OraSure Technologies, Inc. (NASDAQ:OSUR) Director John P. Kenny purchased 47,659 shares of the stock in a transaction on Thursday, February 27th. The stock was acquired at an average price of $3.17 per share, with a total value of $151,079.03. Following the completion of the acquisition, the director now directly owns 70,915 shares of the company’s stock, valued at approximately $224,800.55. This represents a 204.93 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

OraSure Technologies Trading Up 2.3 %

Shares of NASDAQ OSUR opened at $3.13 on Friday. The company has a fifty day moving average price of $3.78 and a 200 day moving average price of $4.01. The firm has a market cap of $233.48 million, a PE ratio of 20.87 and a beta of 0.05. OraSure Technologies, Inc. has a 1-year low of $2.68 and a 1-year high of $8.04.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, February 22nd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its position in OraSure Technologies by 202.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 5,234 shares during the last quarter. Causeway Capital Management LLC bought a new position in shares of OraSure Technologies during the 4th quarter worth approximately $36,000. Raymond James Financial Inc. acquired a new stake in shares of OraSure Technologies in the fourth quarter valued at approximately $37,000. Atom Investors LP bought a new stake in shares of OraSure Technologies in the third quarter worth $49,000. Finally, Boothbay Fund Management LLC acquired a new position in OraSure Technologies during the fourth quarter worth $42,000. 93.50% of the stock is owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.